AbbVie Inc., US00287Y1091

AbbVie stock: Piper Sandler raises target to USD 349

Published on 11/19/2026 at 15:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock is in focus after Piper Sandler raised its target and retained an Overweight rating. Pipeline durability remains central to the view.

What investors are watching

  • Piper Sandler kept an Overweight rating while pointing to AbbVie's long-term immunology pipeline.
  • Skyrizi combinations and zumilokibart are central to the firm's view of franchise durability.
  • AbbVie stock traded below the previous Xetra close on Lang & Schwarz Thursday afternoon.
AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie stock traded at 259.15 euros on Lang & Schwarz at 15:33 CET on Thursday, November 19, 2026, 1.54 percent below the Xetra close of 263.20 euros on Wednesday, November 18. The quote was also 2.02 percent below the 264.50-euro Lang & Schwarz price in the previous report published on November 18.

Markets Insider reported that Piper Sandler raised its AbbVie price target from USD 303 to USD 349 on November 18 and retained an Overweight rating. The analyst action followed AbbVie's third-quarter update.

Pipeline remains central

Piper Sandler cited AbbVie's top-line and EBITDA growth profile through the end of the decade. The firm also pointed to greater visibility for Skyrizi-containing combination products in inflammatory bowel disease and their potential implications for the immunology franchise.

The note highlighted zumilokibart in atopic dermatitis and other indications. Those programs are relevant to the longer-term durability of AbbVie's immunology business as investors assess eventual exclusivity risks for established products.

Third-quarter backdrop

AbbVie reported third-quarter revenue of USD 17.4 billion, with Skyrizi and Rinvoq among the main growth drivers, according to the previous company coverage. Management also raised its 2026 adjusted earnings outlook, providing the operating backdrop for recent analyst actions.

For investors, the revised analyst view raises the importance of pipeline execution and commercial follow-through. The valuation case depends on whether newer immunology products can extend growth while established medicines face pricing and patent-related pressure.

Broader market developments can shape healthcare valuations; see Current market reports.

More news and analyses on AbbVie stock.

AbbVie Inc. stock facts

  • Company: AbbVie Inc.
  • ISIN: US00287Y1091
  • Ticker: ABBV
  • Home exchange: NYSE
  • Trading venue: Lang & Schwarz
  • Quote: 259.15 euros at 15:33 CET on November 19, 2026
  • Change versus previous report: 2.02 percent lower than 264.50 euros at 16:02 CET on November 18, 2026
  • Xetra close: 263.20 euros on November 18, 2026
  • Analyst target: USD 349 from USD 303
  • Rating: Overweight
Disclaimer...
en | US00287Y1091 | ABBVIE INC. | boerse | 70536660 | bgmi